EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 141 filers reported holding EDGEWISE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,800,121 | +15.4% | 710,723 | +16.9% | 0.51% | +31.6% |
| Q1 2024 | $11,090,139 | -5.7% | 608,012 | -43.4% | 0.39% | +0.3% |
| Q4 2023 | $11,759,494 | +118.5% | 1,074,908 | +14.5% | 0.39% | +102.1% |
| Q3 2023 | $5,381,198 | +7.7% | 939,127 | +45.7% | 0.19% | +24.7% |
| Q2 2023 | $4,996,526 | +2.1% | 644,713 | -12.1% | 0.15% | +3.4% |
| Q1 2023 | $4,893,539 | – | 733,664 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |